Medical optimization of lumbar fusion in the osteoporotic patient
- 162 Downloads
In patients undergoing lumbar fusion, osteoporosis has been shown to lead to poorer outcomes and greater incidence of fusion-related complications. Given the undesirable effect of osteoporosis on lumbar fusion surgery, a number of medications have been proposed for use in the peri- and postoperative period to mitigate risks and enhance outcomes. The purpose of this review was to summarize and synthesize the current literature regarding medical management of osteoporosis in the context of lumbar fusion surgery.
A literature search of PubMed, Embase, and Web of Science was conducted in October 2016, using permutations of various search terms related to osteoporosis, medications, and lumbar fusion.
Teriparatide injections may lead to faster, more successful fusion, and may reduce fusion-related complications. Bisphosphonate therapy likely does not hinder fusion outcomes and may be useful in reducing certain complications of fusion in osteoporotic patients. Calcitonin and selective estrogen receptor modulator therapy show mixed results, but more research is necessary to make a recommendation. Vitamin D deficiency is associated with poor fusion outcomes, but evidence for supplementation in patients with normal serum levels is weak.
Overall, the current body of research appears to support the use of teriparatide therapy to enhance lumbar fusion outcomes in the osteoporotic patient, although the extent of research on this topic is limited. Additionally, very little evidence exists to cease any of the mentioned osteoporosis treatments prior to lumbar fusion.
KeywordsOsteoporosis Lumbar spine Lumbar fusion Medical treatment Fusion rate Bone mineral density Teriparatide Bisphosphonates Selective estrogen receptor modulators Calcitonin Vitamin D
Compliance with ethical standards
Conflicts of interest
- 1.Centers for Disease Control. Percentage of adults aged 65 and over with osteoporosis or low bone mass at the femur neck or lumbar spine: United States, 2005–2010 [Centers for Disease Control web site]. August 2015. Available at: http://www.cdc.gov/nchs/data/hestat/osteoporsis/osteoporosis2005_2010.htm Accessed October 13th, 2016
- 2.Office of the Surgeon General (US). Bone health and osteoporosis: a report of the surgeon general. Rockville (MD): Office of the Surgeon General (US); 2004. Reports of the Surgeon GeneralGoogle Scholar
- 3.Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML, Chen YT (2006) The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17:565–574CrossRefPubMedGoogle Scholar
- 13.Andersen T, Christensen FB, Langdahl BL, Ernst C, Fruensgaard S, Østergaard J, Andersen JL, Rasmussen S, Niedermann B, Høy K, Helmig P, Holm R, Lindblad BE, Hansen ES, Egund N, Bünger C (2010) Fusion mass bone quality after uninstrumented spinal fusion in older patients. Eur Spine J 19(12):2200–2208CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Schreiber JJ, Hughes AP, Taher F et al (2014) An association can be found between Hounsfield units and success of lumbar spine fusion. Hospital Spec Surg 10(1):25–29Google Scholar
- 21.Oh KW, Lee JH, Lee JH, et al (2016) The correlation between cage subsidence, bone mineral density, and clinical results in posterior lumbar interbody fusion. Clin Spine SurgGoogle Scholar
- 22.Park SJ, Lee CS, Chung SS, et al (2016) Different risk factors of proximal junctional kyphosis and proximal junctional failure following long instrumented fusion to the sacrum for adult spinal deformity: survivorship analysis of 160 patients. NeurosurgeryGoogle Scholar
- 24.Toyone T, Ozawa T, Kamikawa K, Watanabe A, Matsuki K, Yamashita T, Shiboi R, Takeuchi M, Wada Y, Inada K, Aoki Y, Inoue G, Ohtori S, Tanaka T (2010) Subsequent vertebral fractures following spinal fusion surgery for degenerative lumbar disease: a mean ten-year follow-up. Spine 35(21):1915–1918CrossRefPubMedGoogle Scholar
- 34.Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, Aoki Y, Nakamura J, Miyagi M, Suzuki M, Kubota G, Inage K, Sainoh T, Sato J, Shiga Y, Abe K, Fujimoto K, Kanamoto H, Inoue G, Takahashi K (2015) More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. Asian Spine J 9(4):573–580CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Cho PG, Ji GY, Shin DA, Ha Y, Yoon DH, Kim KN (2015) An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data. Eur Spine J 26:691–697. https://doi.org/10.1007/s00586-015-4342-y CrossRefPubMedGoogle Scholar
- 37.Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K (2013) Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine 38(8):E487–E492CrossRefPubMedGoogle Scholar
- 41.Ebata S, Takahashi J, Hasegawa T, Mukaiyama K, Isogai Y, Ohba T, Shibata Y, Ojima T, Yamagata Z, Matsuyama Y, Haro H (2017 Mar 1) Role of weekly teriparatide administration in osseous union enhancement within six months after posterior or transforaminal lumbar interbody fusion for osteoporosis-associated lumbar degenerative disorders: a multicenter, prospective randomized study. J Bone Joint Surg 99(5):365–372. https://doi.org/10.2106/JBJS.16.00230 CrossRefPubMedGoogle Scholar
- 43.Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87(10):4528–4535CrossRefPubMedGoogle Scholar
- 44.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441CrossRefPubMedGoogle Scholar
- 50.Yishake M, Yasen M, Jiang L, Liu W, Xing R, Chen Q, Lin H, Dong J (2017 Aug 10) Effects of combined teriparatide and zoledronic acid on posterior lumbar vertebral fusion in an aged ovariectomized rat model of osteopenia. J Orthop Res. https://doi.org/10.1002/jor.23682